Viscosupplementation Treatment for Arthritis Market Report 2026

The viscosupplementation treatment for arthritis market size has grown strongly in recent years. It will grow from $4.18 billion in 2025 to $4.5 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to rising prevalence of osteoarthritis, increasing aging population, early clinical adoption of hyaluronic acid injections, growth of orthopedic treatment practices, availability of injectable joint therapies.

The viscosupplementation treatment for arthritis market size is expected to see strong growth in the next few years. It will grow to $5.98 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing demand for non-surgical arthritis treatments, rising healthcare expenditure on musculoskeletal disorders, expansion of outpatient orthopedic services, growing focus on quality-of-life improvement, ongoing innovation in viscosupplement formulations. Major trends in the forecast period include growing adoption of single-injection treatment regimens, rising demand for long-lasting pain relief solutions, expansion of minimally invasive arthritis therapies, increased focus on improved joint lubrication formulations, enhanced emphasis on patient-centric treatment approaches.

The rising prevalence of osteoarthritis is expected to drive the growth of the viscosupplementation treatment for arthritis market in the coming years. Osteoarthritis is a chronic joint condition marked by gradual cartilage degeneration, causing pain, stiffness, and reduced mobility. The increase in osteoarthritis cases is largely due to an aging population, as the natural wear and tear on joints over time makes older adults more vulnerable to the disease. Viscosupplementation treatment for arthritis helps manage osteoarthritis by restoring joint lubrication, reducing pain, and enhancing mobility. For example, in February 2025, Springer Nature Group, a UK-based academic and professional publisher, estimated that knee osteoarthritis affected 12.94 million males and 18.8 million females. By 2046, these numbers are projected to rise to 18.45 million males and 25.6 million females. Therefore, the growing prevalence of osteoarthritis is fueling the growth of the viscosupplementation treatment for arthritis market.

Rising healthcare expenditure is also expected to support the growth of the viscosupplementation treatment for arthritis market. Increased healthcare spending is driven by the growing burden of chronic diseases, which require long-term management and ongoing therapeutic interventions. Higher healthcare expenditure facilitates access to advanced treatments, funds innovative research, and improves patient affordability for effective osteoarthritis management. For instance, in June 2025, the Centers for Medicare & Medicaid Services, a US-based government agency, reported that national health expenditures (NHE) rose by 7.5% in 2023 to $4.9 trillion, averaging $14,570 per person and accounting for 17.6% of the Gross Domestic Product (GDP). Medicare spending increased by 8.1% to $1.02 trillion, representing 21% of total NHE. Consequently, rising healthcare expenditure is driving the growth of the viscosupplementation treatment for arthritis market.

Key players in the viscosupplementation treatment for arthritis market are focusing on innovative solutions such as advanced hyaluronic acid formulations to improve joint lubrication, reduce pain, and enhance mobility. These advanced formulations are designed with optimized molecular structure and viscosity to provide longer-lasting joint lubrication and more effective pain relief. For example, in February 2024, IBSA Group, a Switzerland-based pharmaceutical company, launched the SINOVIAL range, a next-generation viscosupplementation treatment for musculoskeletal conditions. This range uses NAHYCO technology, which combines high and low molecular weight hyaluronic acid to deliver effective joint lubrication and extended pain relief. Mimicking the functions of natural synovial fluid, these treatments enhance joint cushioning and shock absorption. The injectable formulation offers optimal viscosity and high tolerability, supporting improved patient comfort, mobility, and management of osteoarthritis and other musculoskeletal disorders.

Major companies operating in the viscosupplementation treatment for arthritis market are Johnson And Johnson, Sanofi S.A., LG Chem Ltd., Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Zimmer Biomet Holdings Inc., IBSA Group, Bioventus Inc., Fidia Farmaceutici S.p.A., Ferring Pharmaceuticals A/S, Anika Therapeutics Inc., TRB Chemedica International S.A., Laboratoires VIVACY, Seikagaku Corporation, Regen Lab SA, Genzyme Corporation, Medtronic PLC, Orthogenix Inc., Hyundai Pharm Co. Ltd., DePuy Synthes.

North America was the largest region in the viscosupplementation treatment for arthritis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viscosupplementation treatment for arthritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viscosupplementation treatment for arthritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the viscosupplementation treatment for arthritis market by increasing costs of imported hyaluronic acid raw materials, sterile syringes, medical-grade polymers, and packaging components. Healthcare providers and manufacturers in North America and Europe are most affected due to reliance on imported pharmaceutical inputs, while Asia-Pacific faces cost pressures on production and distribution. These tariffs are raising treatment costs and affecting pricing strategies. However, they are also encouraging domestic sourcing of biomaterials, localized manufacturing of injectable therapies, and increased investment in regional pharmaceutical production capabilities.

The viscosupplementation treatment for arthritis market research report is one of a series of new reports that provides viscosupplementation treatment for arthritis market statistics, including viscosupplementation treatment for arthritis industry global market size, regional shares, competitors with a viscosupplementation treatment for arthritis market share, detailed viscosupplementation treatment for arthritis market segments, market trends and opportunities, and any further data you may need to thrive in the viscosupplementation treatment for arthritis industry. This viscosupplementation treatment for arthritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Viscosupplementation treatment for arthritis is a medical therapy in which a gel-like substance, typically hyaluronic acid, is injected into a joint to enhance lubrication and reduce pain. This treatment helps restore the joint’s natural cushioning and shock-absorbing properties, particularly in osteoarthritis. It is often used when conventional treatments, such as pain medications or physical therapy, are insufficient to manage joint discomfort and stiffness.

The main product types of viscosupplementation treatment for arthritis include single-injection, three-injection, and five-injection therapies. Single-injection treatment involves administering a single dose of hyaluronic acid or a similar lubricant into the joint to reduce pain, improve mobility, and restore cushioning. Applications include knee osteoarthritis, hip osteoarthritis, shoulder osteoarthritis, and others, with end users including hospitals, ambulatory surgical centers, orthopedic clinics, and similar healthcare facilities.

The viscosupplementation treatment for arthritis market consists of revenues earned by entities by providing services such as joint assessment and imaging services, physical therapy support, post-injection monitoring and follow-up, arthroscopic guidance services, and customized treatment planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The viscosupplementation treatment market also includes sales of hyaluronic acid injections, cross-linked hyaluronic acid formulations, multi-dose hyaluronic acid syringes, combination therapies, and biologically derived viscosupplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.